Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy

Jianghua Wu; Lu Tang; Mengyi Du; Chenggong Li; Haiming Kou; Huiwen Jiang; Wenjing Luo; Yinqiang Zhang; Zhongpei Huang; Danying Liao; Wei Xiong; Heng Mei; Yu Hu

doi:10.1002/ctm2.1225

Plasma proteomic and metabolomic signatures of B-ALL patients during CAR-T cell therapy

Clin Transl Med. 2023 Mar;13(3):e1225. doi: 10.1002/ctm2.1225.

Authors

Jianghua Wu^{1

2}, Lu Tang^{1

2}, Mengyi Du^{1

2}, Chenggong Li^{1

2}, Haiming Kou^{1

2}, Huiwen Jiang^{1

2}, Wenjing Luo^{1

2}, Yinqiang Zhang^{1

2}, Zhongpei Huang^{1

2}, Danying Liao^{1

2}, Wei Xiong², Heng Mei^{1

2}, Yu Hu^{1

2}

Affiliations

¹ Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
² Hubei Clinical Medical Center of Cell Therapy for Neoplastic Disease, Wuhan, China.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antigens, CD19
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive
Proteomics
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen
Antigens, CD19

Publication types

MeSH terms

Substances

Grants and funding